OVARIAN CLEAR CELL ADENOCARCINOFIBROMA
Clinical trials for OVARIAN CLEAR CELL ADENOCARCINOFIBROMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN CLEAR CELL ADENOCARCINOFIBROMA trials appear
Sign up with your email to follow new studies for OVARIAN CLEAR CELL ADENOCARCINOFIBROMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Weekly vs. Every-3-Weeks chemo: which works better for ovarian cancer?
Disease control OngoingThis phase III trial tested two different schedules of the chemotherapy drug paclitaxel (weekly vs. every three weeks) combined with carboplatin, with or without the targeted drug bevacizumab, in 692 patients with advanced ovarian, peritoneal, or fallopian tube cancer. The goal w…
Matched conditions: OVARIAN CLEAR CELL ADENOCARCINOFIBROMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for recurrent ovarian cancer: drug combo and surgery may extend life
Disease control OngoingThis study looked at adding the drug bevacizumab to standard chemotherapy (carboplatin and paclitaxel or gemcitabine) and surgery for people with ovarian, peritoneal, or fallopian tube cancer that came back after initial treatment. Over 1,000 participants were randomly assigned t…
Matched conditions: OVARIAN CLEAR CELL ADENOCARCINOFIBROMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC